60 results about "Lens epithelial cell" patented technology

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

Generally, an intraocular implant and methods for treating an ocular condition. As to certain embodiments, an intraocular biocompatible biodegradable implant (11) which can provide a biocompatible biodegradable material in the form of a flexible membrane (12) containing an active agent (24) which implanted between an intraocular lens (8) and the surface of the posterior capsule (5) of the eye (1)(4) inhibits migration of residual lens epithelial cells after cataract surgery by providing structural or pharmaceutical barriers to reduce posterior capsule (5) opacification of the eye (1)(4).

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

Photodynamic therapy to prevent secondary cataracts is effected using photosensitizers such as green porphyrins as photoactive agents to destroy remnant lens epithelial cells.

A method and apparatus for directing relatively gentle pulses of heated surgical fluid against the capsular bag to assist in the removal of lens epithelial cells and cortical material adhered to the capsular bag.

An artificial lens having stents coated with antiproliferative agents for prevention and treatment of the posterior capsule opacification, the invention relates to an artificial lens having stents coating for solving problems of time of present artificial lens loaded with medicine acting on cornea is short. The artificial lens having stents coated with antiproliferative agents for prevention and treatment of the posterior capsule opacification is prepared by ordinary artificial lens and coating with antiproliferative agents, wherein the coating with antiproliferative agents adheres on surface of ordinary artificial lens, thickness of the coating is 3 to 20 mum. The invention adopts macomolecule coating material to coat antiproliferative agents on artificial lens, slowly releases agents in capsules and ambitus cells, represses generation of lens epithelial cell, prevents and cures formation of the posterior capsule opacification. The agents of the invention act on cornea long time, capable of releasing effectively 90 to 120 days, have good therapeutic, patients use the artificial lens of the invention, formation rate of the posterior capsule opacification reduced greatly from more than 60% to 10% and without untoward reaction.

Surface modified medical devices such as intraocular lens implants formed from one or more functional group-containing materials using reactive, hydrophilic polymers with catalyst functionality for the purpose of reducing or eliminating lens epithelial cell growth thereon, reducing or eliminating silicone oil absorption upon subsequent surgical exposure and / or reducing implantation inserter friction is provided herein. Additionally, a method of making and using surface modified intraocular lens implants is provided.

Generally, an intraocular implant having on the external surface a plurality of pattern surface elements disposed in spaced apart relation defining a tortuous pathway adapted to control a flow of fluid, or a flow of particles suspended in a fluid, or inhibits the growth or migration of cells. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits growth or migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

Several methods for preventing, minimizing, or delaying the incidence of posterior capsule opacification are provided. A first method involves chemically activating the surface of an implantable ocular device, such as an intraocular lens or a capsular tension ring, by grafting a chemical moiety onto the surface of the device, covalently attaching a non-cytotoxic inhibitor compound to the chemical moiety to produce an inhibitor implantable ocular device, and implanting this inhibitor implantable ocular device into the capsular bag of an eye of a patient during extracapsular cataract surgery. Appropriate inhibitor compounds include RGD mimetics, RGD peptides, and flavonoids. A second method involves surface modifying the exterior surface of a capsular tension ring by covalently attaching a mitotic inhibitor, preferably a conjugate of methotrexate and a bovine serum albumin, and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. A third method involves surface modifying the exterior surface of a capsular tension ring by coating or grafting the exterior surface with a charged polyethylamine and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. An implantable ocular device according to the invention, such as an intraocular lens or a capsular tension ring, contains a substrate with a chemical moiety grafted thereon and a non-cytotoxic inhibitor compound covalently bonded to the chemical moiety or contains a substrate modified with a mitotic inhibitor or charged polyethylamine. The inhibitor devices inhibits proliferation and migration of lens epithelial cells on the posterior capsule of the eye of the patient, thereby preventing, minimizing, or delaying the onset of posterior capsule opacification.

Photodynamic therapy to prevent secondary cataracts is effected using photosensitizers such as green porphyrins as photoactive agents to destroy remnant lens epithelial cells.

The invention relates to a modification process of a surface bionic self-assembly multilayer film of an artificial lens and the artificial lens provided with the surface bionic self-assembly multilayer film. The modification process of the surface bionic self-assembly multilayer film of the artificial lens comprises the following steps: the well cleaned artificial lens is provided with positive charge through surface pre-treatment, soaked into biomacromolecule polyelectrolyte solution provided with negative charge, placed still for electrostatic adsorption for a period of time, taken out and cleaned; then the artificial lens is soaked into biomacromolecule polyelectrolyte solution provided with positive charge, placed still for electrostatic adsorption for a period of time, taken out and cleaned; the alternative electrostatic assembly process is repeated for several times, at last the artificial lens is dried at room temperature, and the artificial lens modified by the surface bionic self-assembly multilayer film is obtained. The modification process of the surface bionic self-assembly multilayer film of the artificial lens and the artificial lens provided with the surface bionic self-assembly multilayer film have the advantages that a bionic modification layer formed by an artificial lens surface bionic lens envelope is obtained through a simple, convenient and rapid bionic method, adhesion and breeding of impedance lens epithelial cells are achieved, toxic and side effects on non-target cells existing in the application of a drug coating artificial lens are avoided, and the obtained artificial lens is high in biological compatibility.

Compositions and methods for inhibiting the growth of lens epithelial cells are provided. The compositions provided include a chelating agent in an amount sufficient for inhibiting the growth of lens epithelial cells. The compositions and methods provided may also be used for the treatment of disorders of the eye, especially in the treatment of presbyopia.

A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.

The invention relates to a preparation method of a chitosan-coated heat-reducing nano-silver multilayer film long-acting antibacterial coating. The coating is prepared by using a solution of polyacrylic acid and chitosan-silver nitrate and a layer-by-layer self-assembly method; the heat-reducing nano-silver organic-inorganic hybrid hydrogel coating is obtained by using a heating way. By coating the surface of a multilayer film with a layer of chitosan, the release rate of nano-silver is controlled, and the biocompatibility of the multilayer film is improved. Silver ions have a broad-spectrum antibacterial function, so that the slow release of the silver ions enables the multilayer film to have an efficient and long-acting antibacterial ability for gram-positive and gram-negative bacteria; By coating the surface with the layer of chitosan, the cytotoxicity for fibroblasts and human lens epithelial cells can be reduced, and the biocompatibility is improved. The method is simple and fast in technology and easy to smear, dip and spray, can be implemented in an industrial way, and has wide application scope; the chitosan-coated heat-reducing nano-silver multilayer film long-acting antibacterial coating can effectively improve the antibacterial property and biocompatibility of the surface of a medical device.

The invention discloses an artificial crystalline lens used for preventing and / or treating posterior capsule opacification and a preparation method of the artificial crystalline lens. Trypsin is fixed on the surface of the artificial crystalline lens, namely the trypsin which has a lethal effect on crystalline lens epithelial cells is fixed on the surface of the artificial crystalline lens. Therefore, the artificial crystalline lens can selectively destroy the crystalline lens epithelial cells in a lens capsule when the artificial crystalline lens is transplanted into the lens capsule. Occurring of posterior capsular opacification is avoided.

The invention provides an iron-based magnetic nano-particles regionally modified intraocular lens and a preparation method and application thereof. The intraocular lens comprises an intraocular lens body and iron-based magnetic nano-particles for coating of a connection layer, which is connected to the equatorial region of the intraocular lens body. The intraocular lens is obtained through hydroxyl modification of the equatorial region of the intraocular lens body and chemical bonding of the iron-based magnetic nano-particles. The intraocular lens has no influence on optical performance of the intraocular lens body, has good biocompatibility, can controllably kill lens epithelial cells at real time, and can effectively reduce recurrence rate of cataract so as to solve the great clinic problem of after-cataract. The intraocular lens enables chemicals to selectively act on the lens epithelial cells rather than damage other intraocular tissues. The invention provides a new idea, a new approach and a new method for prevention of after-cataract.

The invention provides an intraocular lens regionally modified by a gold nanorod, and a preparation method and application thereof. The intraocular lens comprises an intraocular lens body and the gold nanorod coated by a connection layer, wherein the connection layer is connected with the equatorial region of the intraocular lens body. The intraocular lens is prepared by subjecting the equatorial region of the intraocular lens body to hydroxyl modification and then to chemical bonding with the gold nanorod. The intraocular lens regionally modified by the gold nanorod poses no influence on the optical performance of the intraocular lens body, has good biological compatibility, can realize real-time controllable killing of lens epithelial cells and effectively reduce the recurrence rate of cataract, and overcomes the serious clinical problem of after cataract. The intraocular lens enables chemicals to selectively act on the lens epithelial cells without injuring other tissue in eyes and provides a novel thought, approach and method for prevention of after cataract.

The invention discloses a drug-modified intraocular lens and a preparation method and application thereof. According to the intraocular lens, by researching the effect of a signal path on proliferation and migration of lens epithelial cells, a drug with a prevention and treatment effect on posterior capsule opacification after cataract surgery is screened out. It is found that an inhibitor of a ROCK signal path has an influence on the proliferation and migration of the lens epithelial cells, and the drug-modified intraocular lens is provided by improving a drug feeding mode. The intraocular lens can relatively controllably release the explosive drug in the early stage; moreover, by slowly releasing the drug in the later stage, the intraocular lens integrally has the advantages of great biocompatibility and good prevention and treatment effect.

A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.

The invention provides a device for preventing and treating posterior capsule opacification. The device for preventing and treating the posterior capsule opacification comprises a container, a heat insulation pipe and an elastic membrane. An outlet end is arranged on the container. A piston which is used for squeezing out contents in the container from the output end is arranged inside the container. Two ends of the heat insulation pipe are open, wherein one end is connected with the output end of the container. The heat insulation pipe is outside sealed, the elastic membrane is arranged at the other end of the heat insulation pipe, or the elastic membrane is a test-tube-shaped elastic membrane which is arranged inside the heat insulation pipe. The test-tube-shaped elastic membrane bulges out of the heat insulation pipe to form a bubble under the action of the piston, wherein trypsin is fixed on the outer surface of the bubble which is formed by the elastic membrane. The device for preventing and treating the posterior capsule opacification can selectively remove crystalline lens epithelial cells in extracapsular cataract extraction, and therefore occurring of posterior capsular opacification is avoided.

The invention belongs to the field of biomedicines and particularly relates to an application of lunasin polypeptide in a medicine for preventing and treating cataract. Lunasin is an active peptide initially separated from soybeans and consists of 43 amino acid residues. Besides the anti-tumor and anti-inflammatory pharmacological activity, the lunasin further has a strong antioxidative stress function. Animal in vivo pharmacodynamic experiments verify that eye drops prepared by lunasin can effectively inhibit cataract induced by D-galactose. Meanwhile, in the cellular level, the lunasin polypeptide can effectively protect the damage of high concentration D-galactose to human lens epithelial cells, inhibit apoptosis of the human lens epithelial cells and remarkably up-regulate expression of an antioxidase gene (for example, superoxide dismutase, hydrogen peroxidase, glutathione S-transferase, glutathion peroxidase and peroxidase).

The invention relates to new application of geldanamycin and a derivative thereof in treating and inhibiting posterior capsular opacification, belonging to the technical field of medicines. Experiments prove that a geldanamycin derivative 17AAG inhibits human lens epithelial cells from proliferating and induces lens epithelial cells to die; in an in vitro rat lens capsular bag cultivation model, 17AAG inhibits residual lens epithelial cells from proliferating, migrating and fiberizing in a lens posterior capsule greatly, induces cells with posterior capsule overgrown to die, and promotes turbid lens posterior capsule to recover transparency; in a rabbit intraocular lens replacement model, 17AAG can inhibit posterior capsular opacification. The geldanamycin and the derivative thereof inhibit posterior capsular opacification by inhibiting HSP90 molecular chaperone activity of lens cells, and have a therapeutical effect on the formed posterior capsular opacification at the same time. 17AAG has new application in treating posterior capsular opacification, and is a candidate medicine that 17AAG has development potential and can prevent and treat posterior capsular opacification.

Surface modified medical devices such as intraocular lens implants formed from one or more functional group-containing materials using reactive, hydrophilic polymers with catalyst functionality for the purpose of reducing or eliminating lens epithelial cell growth thereon, reducing or eliminating silicone oil absorption upon subsequent surgical exposure and / or reducing implantation inserter friction is provided herein. Additionally, a method of making and using surface modified intraocular lens implants is provided.

A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.

The invention discloses a preparation method of a high-efficiency medicament carrier material based on enzyme-degrading bacterium micro-environmental response. According to the preparation method of the high-efficiency medicament carrier material based on the enzyme-degrading bacterium micro-environmental response, small molecular gentamycin is loaded in a membrane, and the membrane is degraded under the stimulation of bacteria or chymotrypsin to release a medicament so as to realize a high-efficiency and long-term sterilizing function on gram-negative bacteria, gram-positive bacteria as wellas fungi. A medicament carrier has an enzyme and bacterial injection response medicament release effect, can realize controllability of medicament release, and avoids medicament resistance. The medicament carrier can realize broad-spectrum antibacterial capacity and controllable medicament release capacity; polylysine with good biocompatibility is added, so that the cellular compatibility of the medicament carrier is improved, and the medicament carrier shows low cytotoxicity on the lens epithelial cells and desmocytes. The preparation method is simple, has good repeatability and wide application range, and can perform coating modification on a biomedical device with a complex haplotype structure.